4-(1-aminoethyl)benzenesulfonamide hydrochloride | 116599-30-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(1-aminoethyl)benzenesulfonamide hydrochloride
• 英文别名: 4-(1-amino-ethyl)-benzenesulfonic acid amide; hydrochloride；4-(1-Amino-aethyl)-benzolsulfonsaeure-amid; Hydrochlorid；4-(1-Aminoethyl)benzene-1-sulfonamide hydrochloride；4-(1-aminoethyl)benzenesulfonamide;hydrochloride
• CAS: 116599-30-5
• 化学式: C₈H₁₂N₂O₂S*ClH
• 分子量: 236.722
• InChiKey: KBEDWXLKBDLBEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.78
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  94.6
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(1-aminoethyl)benzenesulfonamide hydrochloride 以 吡啶 、 丁酮 为溶剂， 生成 {4-[1-(5-methyl-isoxazole-3-carbonylamino)-ethyl]-benzenesulfonyl}-carbamic acid methyl ester
  参考文献：
  名称：

  Pluempe; Horstmann; Puls, Arzneimittel-Forschung/Drug Research, 1974, vol. 24, # 0, p. 363 - 374

  摘要：

  DOI：

文献信息

• Adenosine receptor ligands and their use in the treatment of disease
  申请人：——

  公开号：US20010027196A1

  公开（公告）日：2001-10-04

  The invention relates to cyclic heteroaromatic compounds, containing at least one nitrogen atom, and to their use in the manufacture of medicaments for the treatment of diseases, related to adenosine receptor modulators, such as Alzheimer's disease, Parkinson's disease, neuroprotection, schizophrenia, anxiety, pain, respiration deficits, depression, asthma, allergic responses, hypoxia, ischaemia, seizure, substance abuse, sedation and they may be active as muscle relaxants, antipsychotics, anti epileptics, anticonvulsants and cardiaprotective agents.

  这项发明涉及含有至少一个氮原子的环状杂芳化合物，以及它们在制造用于治疗与腺苷受体调节剂相关的疾病的药物中的应用，如阿尔茨海默病、帕金森病、神经保护、精神分裂症、焦虑、疼痛、呼吸功能障碍、抑郁症、哮喘、过敏反应、缺氧、缺血、癫痫、物质滥用、镇静，它们可能作为肌肉松弛剂、抗精神病药、抗癫痫药、抗惊厥药和心脏保护剂而具有活性。
• Tyrosine kinase inhibitors
  申请人：Dinsmore J. Christopher

  公开号：US20060128783A1

  公开（公告）日：2006-06-15

  The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

  本发明涉及能够抑制、调节和/或调节受体型和非受体型酪氨酸激酶信号转导的化合物。本发明所述化合物具有包含吲哚磺酰胺基团的核心结构。本发明还涉及这些化合物的药学上可接受的盐、水合物和立体异构体。
• TYROSINE KINASE INHIBITORS
  申请人：Dinsmore Christopher J.

  公开号：US20100041652A1

  公开（公告）日：2010-02-18

  The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.

  本发明涉及一种能够抑制、调节和/或调控受体型和非受体型酪氨酸激酶信号转导的化合物。本发明的化合物具有包含吲哚-磺酰胺基团的核心结构。本发明还涉及这些化合物的药学上可接受的盐、水合物和立体异构体。
• Methods and materials for enhancing the effects of protein modulators
  申请人：Mallik Sanku

  公开号：US20060009918A1

  公开（公告）日：2006-01-12

  Disclosed is a method for enhancing the effect of a protein modulator on a protein by modifying the protein modulator so that the protein modulator binds with the surface of the protein, along with a method for modulating a protein's biological function by contacting the protein with such a modified protein modulator. Also described are modified protein modulators having the formula PM-SP-(LK) p -MCG-(M) q , where PM is a protein modulator which interacts with an active site or allosteric site of a protein; SP is a spacer; LK is a linker; p is 0 or 1; q is an integer greater than or equal to one; MCG is a metal chelating group; and M is a metal ion.

  本发明公开了一种通过修饰蛋白质调节剂使其与蛋白质表面结合从而增强蛋白质调节剂对蛋白质的作用的方法，以及一种通过将蛋白质与这种修饰的蛋白质调节剂接触来调节蛋白质生物功能的方法。还描述了具有以下式子的改性蛋白质调节剂： PM-SP-(LK) p -MCG-（M） q 其中，PM 是与蛋白质的活性位点或异构位点相互作用的蛋白质调节剂；SP 是间隔物；LK 是连接物；p 是 0 或 1；q 是大于或等于 1 的整数；MCG 是金属螯合基团；M 是金属离子。
• Identification of a Series of Compounds with Potent Antiviral Activity for the Treatment of Enterovirus Infections
  作者：Angus M. MacLeod、Dale R. Mitchell、Nicholas J. Palmer、Hervé Van de Poël、Katja Conrath、Martin Andrews、Pieter Leyssen、Johan Neyts

  DOI：10.1021/ml400095m

  日期：2013.7.11

  Rhinovirus (genus enterovirus) infections are responsible for many of the severe exacerbations of asthma and chronic obstructive pulmonary disease. Other members of the genus can cause life-threatening acute neurological infections. There is currently no antiviral drug approved for the treatment of such infections. We have identified a series of potent, broad-spectrum antiviral compounds that inhibit the replication of the human rhinovirus, Coxsackie virus, poliovirus, and enterovirus-71. The mechanism of action of the compounds has been established as inhibition of a lipid kinase, PI4KIII beta. Inhibition of hepatitis C replication in a replicon assay correlated with enterovirus inhibition.